Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05479552 · ClinicalTrials.gov registry record

A Diagnostic Test for Dementia With Lewy Bodies

A clinical trial of MCI-AD, Early Stage Alzheimer's Disease and MCI-DLB, Early Stage Dementia With Lewy Bodies, sponsored by CND Life Sciences.

Active
Registry status
80
Enrollment target
12
Study locations

NCT05479552: Active study of MCI-AD, Early Stage Alzheimer's Disease and MCI-DLB, Early Stage Dementia With Lewy Bodies, sponsored by CND Life Sciences.

NCT05479552 is a study of MCI-AD, Early Stage Alzheimer's Disease and MCI-DLB, Early Stage Dementia With Lewy Bodies that is active but no longer recruiting, run by CND Life Sciences. The registered enrollment target is 80 participants. The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05479552, a study of MCI-AD, Early Stage Alzheimer's Disease and MCI-DLB, Early Stage Dementia With Lewy Bodies, is active but no longer recruiting, sponsored by CND Life Sciences.

ACTIVE NOT RECRUITING
Registry status
80 participants
Enrollment target
12
Study locations

Study Summary

The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

Primary Outcome

To pathologically distinguish DLB from AD early in the course of the disease using the Syn-One TestTM, confirming disease diagnosis through prospective clinical assessments and follow up biopsy analyses over 12 months.

Interventions

  • DIAGNOSTIC_TEST Syn-One Test

Study Locations (12)

Massachusetts

  • Mass General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Headlands Research - Plymouth

Florida

  • University of Miami - Boca Raton
  • Neurology One - Winter Park

Arizona

  • CND Life Sciences - Scottsdale

California

  • University of California San Diego - La Jolla

Colorado

  • CenExel RMCR - Englewood

Louisiana

  • Ochsner Research - New Orleans

Michigan

  • University of Michigan - Ann Arbor

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2022-08-15
Est. Completion 2025-10-31
CND Life Sciences

8 total trials

What the registry record for NCT05479552 still lists

NCT05479552 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.

The record links to 2 conditions, with MCI-AD, Early Stage Alzheimer's Disease appearing as the primary indexed condition, and to 1 intervention - of which Syn-One Test is the first listed.

NCT05479552 lists 12 locations in 9 states (Massachusetts, Florida, Arizona).

Frequently Asked Questions

What is clinical trial NCT05479552 about?

NCT05479552 is a clinical study titled "A Diagnostic Test for Dementia With Lewy Bodies". The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

What is the current status of trial NCT05479552?

This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2022-08-15. Estimated completion is 2025-10-31.

What conditions does trial NCT05479552 study?

This clinical trial studies the following conditions: MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies.

What interventions are being tested in trial NCT05479552?

The interventions under investigation include: Syn-One Test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05479552?

This trial is sponsored by CND Life Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05479552 being conducted?

This trial has 12 study locations across Arizona, California, Colorado, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05479552, the US trial registry maintained by the National Library of Medicine. NCT05479552 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.